Deep Research
EClinCloud research grounded in public raw data, regulatory documents, and peer-reviewed evidence.
ClinicalTrials.gov: Reconcile Outcomes and Adverse-Event DenominatorsReconcile protocol outcomes, registry result tables and adverse-event denominators while distinguishing submission dates from public posting.
Patient Preferences and Postapproval Safety: Keeping the Evidence DistinctInterpret ICH E22, E2D(R1), M14 and FDA pregnancy-safety guidance through study design, case reporting, data provenance and evidence limitations.
Oncology Trial Evidence: Survival, Combination Effects and Study OperationsConnect FDA oncology guidance on survival, component contribution, radiopharmaceutical safety, biopsies and patient outcomes to traceable study operations.
Adaptive and Bayesian Trials: From Statistical Design to Controlled OperationsConnect adaptive and Bayesian trial guidance to justified simulation, independent monitoring, controlled data handoffs and reproducible study operations.
BIMO Inspection or Remote Assessment? Build the Response Around the Actual Request (2026)Classify BIMO inspections, mandatory requests and voluntary remote assessments, then route the actual deadline, access scope and response evidence to an owner.
FDA's 2026 CGM and Immunogenicity-PK Specifications: Preserve the Path from Source to AnalysisDistinguish source observations, missing records and analysis derivations when implementing FDA’s 2026 CGM and immunogenicity-PK dataset recommendations.
COA Qualification and eCOA Release: Keep the Evidence Status Attached to the Instrument (2026)Separate COA qualification, submissions and Compendium evidence, then preserve the instrument’s context of use, version and permission in an eCOA release.
FDA Participation Guidance: Build a Distinct Handoff for Rare-Disease Re-Enrollment (2026)Turn FDA’s rare-disease re-enrollment recommendation into a protocol-specific handoff while preserving prior exposure, selection-bias and authorized-access limits.
Shared controls in 2026 master protocols: why 25% more participants is not 25% more powerRecalculate FDA’s 600-participant shared-control example and preserve concurrent eligibility, consent and allocation history in master-protocol operations.
Pregnancy follow-up in 2026 trial planning: what ICH E21 adds to an E19 data strategyRead ICH E21’s draft alongside E19: pregnancy and infant follow-up, study-specific duration, consent, blinding and post-trial handoffs.
FDA's 2026 oncology eligibility guidance: preserve the clinical rationale in the study buildTranslate FDA’s 2026 oncology eligibility guidance into traceable study rules without inventing thresholds, automatic cohorts or unsafe washout shortcuts.
FDA E2B(R3) in 2026: the routing decision that should come before an EDC rebuildSeparate FDA E2B(R3) reporting scope, ESG and SRP pathways, periodic-report reconciliation and the actual impact on clinical data capture.